Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Solriamfetol in Chinese Patients with OSA-EDS
NCT06103825Phase 3Completed
- Sponsor
- Ignis Therapeutics
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea (OSA) comparing Solriamfetol with Placebo (2 arms). Primary endpoints: Change in Mean Sleep Latency on the Maintenance of Wakefulness Test at 12 weeks and Change in Epworth Sleepiness Scale Score at 12 weeks. Started Aug 2023; status: completed.
02
Drugs
solriamfetol
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT06103825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06103825.